HTA Council Recommendation (as of 26 June 2024) As final recommendation, the HTA Council is recommending the non-financing of the government and non-inclusion of Calcium Hydroxide + Clinoptilolite Larvicide (Kiti-kitiX) in the list of larvicides to be used by the Aedes Borne Viral Diseases (Dengue) Prevention and Control Program of the DOH due to the continue reading : Calcium hydroxide 80% + clinoptilolite 20% (Kiti-kitiX) larvicide [1 bag / 25 kg] for the prevention of dengue
Biannual Ultrasound with Alfa-fetoprotein (AFP) for screening of patients at risk to develop hepatocellular carcinoma who have or have not progressed to cirrhosis
HTA Council Recommendation (as of 28 April 2026) As a final recommendation, the HTA Council positively recommends biannual ultrasound (US) combined with alpha fetoprotein (AFP) test as a screening test for adults at high risk to develop hepatocellular carcinoma (HCC) every 6 months, for financing by DOH and/or PhilHealth. Relevant Information Evidence and Relevant Documents continue reading : Biannual Ultrasound with Alfa-fetoprotein (AFP) for screening of patients at risk to develop hepatocellular carcinoma who have or have not progressed to cirrhosis
Lenvatinib [4 mg/10 mg capsule] for the treatment of advanced or unresectable hepatocellular cancer (HCC) among adults
HTA Council Recommendation (as of 19 January 2026) As a final recommendation, the HTA Council recommends the government financing of Lenvatinib [4 mg/10 mg capsule] as first-line treatment for adults diagnosed with advanced or unresectable HCC who are not candidates for immunotherapy and/oranti-VEGF. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Atezolizumab + Bevacizumab [60 mg/mL, 20 mL vial for IV infusion + 25 mg/mL, 4 mL or 16 mL vial for IV infusion] for the treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
HTA Council Recommendation (as of 19 January 2026) As a final recommendation, the HTA Council recommends the government financing of atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] as preferred first-line treatment for adults diagnosed with advanced or unresectable hepatocellular continue reading : Atezolizumab + Bevacizumab [60 mg/mL, 20 mL vial for IV infusion + 25 mg/mL, 4 mL or 16 mL vial for IV infusion] for the treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
Pneumococcal Conjugate Vaccine (PCV) for elderly adults 60 years old and above
HTA Council Preliminary Recommendation (as of 27 March 2026) As a final recommendation, the HTA Council recommends the government financing of pneumococcal polysaccharide vaccine (PPSV23) for all adults 60 years old and above. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page